Research Topics
Genomes and Genes | N A TerraultSummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners studyNorah A Terrault
Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA
Hepatology 57:881-9. 2013..In addition to the extremely low estimated risk for HCV infection in sexual partners, the lack of association with specific sexual practices provides unambiguous and reassuring counseling messages...- Liver transplantation in the setting of chronic HCVNorah Terrault
University of California San Francisco, United States
Best Pract Res Clin Gastroenterol 26:531-48. 2012.... 
Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfectionNorah A Terrault
University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA
Liver Transpl 18:716-26. 2012..Our results indicate that HCV per se is not a contraindication to LT in HIV patients, but recipient and donor selection and the management of acute rejection strongly influence outcomes...- Benefits and risks of combination therapy for hepatitis BNorah A Terrault
Departments of Medicine and Surgery, University of California San Francisco, San Francisco, CA 94143 0538, USA
Hepatology 49:S122-8. 2009..There is insufficient evidence to recommend combination therapy as first-line therapy for all patients with chronic hepatitis B... 
Treatment of recurrent hepatitis C in liver transplant recipientsNorah A Terrault
Division of Gastroenterology, University of California at San Francisco, San Francisco, CA 94143 0538, USA
Clin Gastroenterol Hepatol 3:S125-31. 2005..Overall, the treatment of HCV disease in transplant recipients leaves much to be desired and there is an urgent need of new HCV therapies in this patient population...- Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantationNorah A Terrault
Department of Medicine, University of California at San Francisco, San Francisco, CA 64143 0538, USA
Liver Transpl 12:801-7. 2006..In HIV-HBV coinfected patients undergoing LT, HBV recurrence is successfully prevented with combination prophylaxis using HBIG and antivirals... - Hepatitis C therapy before and after liver transplantationNorah A Terrault
Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA
Liver Transpl 14:S58-66. 2008..6. Hepatitis C virus-infected liver transplant recipients represent an important patient population in need of new therapeutics options to prevent patient and graft losses due to recurrent hepatitis C virus disease... - Treating hepatitis C infection in liver transplant recipientsNorah A Terrault
Department of Medicine Gastroenterology, University of California San Francisco, San Francisco, CA, USA
Liver Transpl 12:1192-204. 2006..Liver Transpl 12:1192-1204, 2006. (c) 2006 AASLD... - Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis CNorah A Terrault
Department of Medicine, University of California San Francisco, San Francisco, California 94143 0538, USA
Clin Gastroenterol Hepatol 6:1403-11. 2008..Prior studies suggest the rate of liver fibrosis progression is slower in African Americans (AAs) than Caucasian Americans (CAs) with chronic HCV infection... - The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatmentNorah A Terrault
Department of Medicine, Division of Gastroenterology, University of California, San Francisco, San Francisco, California, USA
Clin J Am Soc Nephrol 2:563-75. 2007..New antiviral agents that can be used in dialysis patients (e.g., ribavirin alternatives) and in the posttransplantation setting (e.g., IFN alternatives) are needed to improve outcomes in these populations... - Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapyN A Terrault
Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, CA 94143 0538, USA
J Viral Hepat 12:465-72. 2005..Additionally, we demonstrated the need for cautious interpretation of stopping rules when the values are at or near the decision thresholds... - Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapyC S Coffin
Liver Unit, Division of Gastroenterology, Department of Medicine, Faculty of Medicine, University of Calgary, AB, Canada
J Viral Hepat 18:415-23. 2011..PBMC may be a sanctuary for wt virus during antiviral therapy, while the liver harbours more drug-resistant viruses. Drug resistance correlates with intrahepatic viral diversity... - Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipientsC S Coffin
Department of Medicine, University of California San Francisco, San Francisco, CA, USA
Am J Transplant 10:1268-75. 2010..Combination HBIG and antivirals is effective as prophylaxis with no clinical evidence of HBV recurrence but low-level HBV DNA is detectable in approximately 50% of recipients... - Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1Hari S Conjeevaram
Division of Gastroenterology, The University of Michigan, Ann Arbor, Michigan 48109 0362, USA
Gastroenterology 131:470-7. 2006..Compared with Caucasian Americans (CA), African Americans (AA) with chronic hepatitis C are less likely to respond to interferon-based antiviral therapy... - Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantationAmandeep K Shergill
Department of Medicine, University of California San Francisco, San Francisco, CA, USA
Am J Transplant 5:118-24. 2005..Future studies should focus on alternative dosing schedules with more aggressive use of adjuvant therapies, including GFs... - HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomesM E Roland
University of California, San Francisco, CA, USA
Am J Transplant 8:355-65. 2008.... - Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohortF Y Yao
Department of Medicine, Division of Gastroenterology, University of California, San Francisco, CA 94143 0538, USA
Hepatology 34:411-6. 2001..However, the small sample size and the use of a retrospective control cohort preclude drawing definitive conclusions. Expedited OLT remains the only viable treatment for lamivudine nonresponders... - Patient, center and geographic characteristics of nationally placed liversJ C Lai
Department of Medicine, Division of Gastroenterology and Hepatology, University of California San Francisco, San Francisco, CA, USA
Am J Transplant 12:947-53. 2012..These findings provide the foundation for a more informed discussion about changing our current liver allocation and distribution policies... - Gender differences in liver donor quality are predictive of graft lossJ C Lai
Department of Medicine, Division of Gastroenterology and Hepatology, University of California San Francisco, San Francisco, CA, USA
Am J Transplant 11:296-302. 2011.... - Management of hepatitis C in liver transplant recipientsA Kuo
Division of Gastroenterology, University of California-San Francisco, San Francisco, CA, USA
Am J Transplant 6:449-58. 2006..Ongoing studies may establish a future role for alternative treatment approaches. Additionally, limited overall efficacy of interferon-based therapy in the transplant setting highlights the urgent need for new drug therapies... - Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantationRyan A McTaggart
Department of Surgery, Division of Transplantation, University of California San Francisco, San Francisco, CA 94143-0780, USA
Liver Transpl 10:975-85. 2004..Alternatively, the association of HCV and EAR may result from an increased frequency of allograft biopsy and may be further exacerbated by inability to accurately diagnose EAR in the setting of recurrent HCV... - Treatment of recurrent hepatitis C after liver transplantationScott W Biggins
Division of Gastroenterology, Department of Medicine, University of California, San Francisco, 513 Parnassus Ave, S357, Box 0538 San Francisco, CA 94143, USA
Clin Liver Dis 9:505-23, ix. 2005..Prophylactic and preemptive therapies, as well as treatment of established recurrent disease, are the strategies reviewed... - Antiviral therapy in patients with chronic hepatitis B and cirrhosisCindy J Lai
Division of General Internal Medicine, University of California San Francisco, S357, 513 Parnassus Avenue, San Francisco, CA 94143-0538, USA
Gastroenterol Clin North Am 33:629-54, x-xi. 2004..The newest oral nucleotide analog, adefovir dipivoxil, has shown excellent efficacy in treatment-naïve and lamivudine-resistant HBV patients and has lower rates of resistance in the short-term... - Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infectionAlexander Kuo
Division of Gastroenterology, University of California, San Diego, CA, USA
Liver Transpl 14:1491-7. 2008..004). We conclude that preemptive antiviral therapy in virologic nonresponders delays the time to subsequent HCV treatment and may confer a reduced risk of fibrosis progression. Further study of preemptive antiviral therapy is warranted... - Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantationNorah A Terrault
Department of Medicine, Division of Gastroenterology, University of California at San Francisco, San Francisco, CA, USA
Liver Transpl 13:122-9. 2007..Important predictors of graft loss in HCV-infected patients were limited LDLT experience, pretransplant HCC, and higher MELD at transplantation... - Serum sodium predicts mortality in patients listed for liver transplantationScott W Biggins
Department of Medicine, University of California-San Francisco, San Francisco, CA 94143, USA
Hepatology 41:32-9. 2005..Addition of serum sodium to MELD increases the ability to predict 3- and 6-month mortality in patients with cirrhosis... - Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA)Tarek Elbeik
Department of Laboratory Medicine, University of California, San Francisco 94110, USA
J Clin Microbiol 42:563-9. 2004..1%), a fold change of 2.6. Thus, the observed fold change between any two consecutive HCV RNA measures is expected to be less than 2.6-fold (equivalent to 0.41 log(10) IU/ml) 95% of the time in clinically stable individuals... - Influence of cannabis use on severity of hepatitis C diseaseJulie H Ishida
Department of Medicine, University of California at San Francisco, San Francisco, California, USA
Clin Gastroenterol Hepatol 6:69-75. 2008..Complications of HCV infection are primarily related to the development of advanced fibrosis and whether cannabis use is a risk factor for more severe fibrosis is controversial... - Treatment of recurrent hepatitis B infection in liver transplant recipientsNorah A Terrault
University of California, San Francisco, CA 64143 0538, USA
Liver Transpl 8:S74-81. 2002..6. Antiviral therapy with two or more suitable agents may minimize the chance for viral resistance; therefore, future therapeutic strategies likely will use combination therapy in the long-term management of recurrent HBV disease... - Sexual activity as a risk factor for hepatitis CNorah A Terrault
Gastroenterology Division, Department of Medicine, University of California, San Francisco, CA 94143, USA
Hepatology 36:S99-105. 2002..Current recommendations about sexual practices are different for persons with chronic HCV infection who are in steady monogamous partnerships versus those with multiple partners or who are in short-term sexual relationships... - Is recurrent hepatitis C worse with living donors?Alexander Kuo
Division of Gastroenterology, University of California, San Diego, 200 West Arbor Drive M C 8413, San Diego, CA 92103, USA
Curr Opin Organ Transplant 14:240-4. 2009..This review will present the current data regarding whether recurrent HCV is worse with living donors... - Alcohol use and hepatitis CMarion G Peters
Department of Gastroenterology, University of California, San Francisco, CA 94143, USA
Hepatology 36:S220-5. 2002..The literature is inadequate to provide definitive recommendations regarding the effect of light to moderate alcohol use in patients with hepatitis C... - Organ donors with positive viral serology or malignancy: risk of disease transmission by transplantationSandy Feng
Department of Surgery, Division of Transplantation, University of California, San Francisco, San Francisco, CA 94143-0780, USA
Transplantation 74:1657-63. 2002 - Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy studyPeter G Stock
Department of Surgery, Division of Transplantation, University of California, San Francisco, California 94143 0780, USA
Transplantation 76:370-5. 2003.... - Management of hepatitis C-infected liver transplant recipients at large North American centres: changes in recent yearsMandana Khalili
Department of Medicine, University of California, San Francisco, CA 94110, USA
Clin Transplant 20:1-9. 2006..We conclude that there is considerable variability in the management of HCV among transplant programs and over time... - New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infectionMandana Khalili
Department of Medicine, University of California San Francisco, San Francisco, CA 94110, USA
Liver Transpl 10:349-55. 2004..However, among those developing de novo persistent diabetes, HCV is one of the most important risk factors. This adds further support to the epidemiological data linking HCV and diabetes... - Pharmacokinetics of tacrolimus co-administered with adefovir dipivoxil to liver transplant recipientsNorah A Terrault
Department of Medicine and Surgery, University of California San Francisco, San Francisco, CA 94143 0538, USA
Liver Int 29:1178-83. 2009..Calcineurin inhibitors are a central component of immunosuppressive therapy... - Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantationNorah A Terrault
University of California San Francisco, San Francisco, CA 64153, USA
Liver Transpl 9:S95-S100. 2003..4. It is unclear whether the preemptive antiviral treatment is superior to delaying treatment until recurrent disease is present and controlled trials addressing this issue are needed... - Kidney and liver transplantation in HIV-infected patients: case presentations and reviewMichelle E Roland
Department of Medicine, University of California, San Francisco, San Francisco, California, USA
AIDS Patient Care STDS 17:501-7. 2003.... - Hepatitis B immune globulin preparations and use in liver transplantationNorah A Terrault
Department of Medicine, University of California, 513 Parnassus Avenue, Room S 537, San Francisco, CA 94143 0538, USA
Clin Liver Dis 7:537-50. 2003..Thus, there remains a need to develop and test new forms of anti-HBs therapy, so that effective but less expensive forms of immunoprophylaxis can be made available... - Evidence-based incorporation of serum sodium concentration into MELDScott W Biggins
University of California San Francisco, San Francisco, California, USA
Gastroenterology 130:1652-60. 2006..CONCLUSIONS: We demonstrate an evidence-based method to incorporate Na into MELD, which provides more accurate survival prediction than MELD alone... - Height contributes to the gender difference in wait-list mortality under the MELD-based liver allocation systemJ C Lai
Division of Gastroenterology and Hepatology, University of California, San Francisco, CA, USA
Am J Transplant 10:2658-64. 2010..Height contributes to this gender disparity, possibly reflecting differences in transplantation rates for shorter individuals... - Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosisDerek Patel
Division of Gastroenterology, Department of Medicine, University of California, 513 Parnassus Avenue, San Francisco, CA 94143-0538, USA
Clin Gastroenterol Hepatol 3:75-84. 2005..By increasing organ availability for timely definitive treatment, LDLT might achieve the greatest gain in life expectancy at acceptable costs. Prioritizing CLT for HCC might increase the population-wide benefits of CLT... - Management of hepatitis B in liver transplant recipientsCarla S Coffin
Department of Medicine, University of California at San Francisco, San Francisco, CA 94143, USA
J Viral Hepat 14:37-44. 2007..There is an increasing need for individualization of therapy based on prior drug exposures, level of HBV DNA at time of transplantation and type of prophylaxis used... - Addition of adult-to-adult living donation to liver transplant programs improves survival but at an increased costPatrick G Northup
Department of Medicine, University of Virginia, Charlottesville, VA, USA
Liver Transpl 15:148-62. 2009..The addition of LDLT to a standard waiting list DDLT program is effective at improving recipient survival and preventing waiting list deaths but at a greater cost... - Mutation of human keratin 18 in association with cryptogenic cirrhosisN O Ku
Department of Medicine, VA Palo Alto Health Care System, California 94304, USA
J Clin Invest 99:19-23. 1997..Our results suggest that mutations in K18 may be predispose to, or result in cryptogenic cirrhosis in humans... - Treating chronic hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapyNorah A Terrault
Division of Gastroenterology, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA
Semin Liver Dis 27:18-24. 2007.... - Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver diseaseShiobhan R Weston
Department of Medicine, University of California at San Francisco, USA
Hepatology 41:372-9. 2005..Clinicians need to be aware of the variable presentations of NAFLD in different racial and ethnic groups... - Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfectionAudrey L French
CORE Center Cook County Hospital, Rush Medical College, Chicago, IL 60612, USA
Clin Infect Dis 39:402-10. 2004..65% to increases of 7.57% of the ULN per year; P values of.19-.71). Our findings lend support to assertions that antiretroviral therapy is safe for women with HCV infection... - Sustained and focused hepatitis B virus nucleocapsid-specific T-cell immunity in liver transplant recipients compared to individuals with chronic and self-limited hepatitis B virus infectionFlorian Bihl
Division of Gastroenterology and Hepatology, University Hospital of Geneva, Geneva, Switzerland
Liver Transpl 14:478-85. 2008..Thus, the profile of the cellular immunity against HBV was in immune suppressed patients similar to subjects with chronic HBV infection with suppressed HBV-DNA... - Antiviral therapy in liver transplant recipients: is SVR the only endpoint that matters?Alexander Kuo
J Hepatol 46:359-61. 2007 - Should HCV-related cirrhosis be a contraindication for retransplantation?Scott W Biggins
Liver Transpl 9:236-8. 2003 - Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver diseaseRolland C Dickson
Division of Gastroenterology and Hepatology, Mayo Clinic Foundation, Jacksonville, FL 32216, USA
Liver Transpl 12:124-33. 2006..In conclusion, this study provides a rationale for the use of lower HBIg doses in HBV patients with suppressed replication undergoing LT... - Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infectionCharles D Howell
University of Maryland Baltimore School of Medicine, Baltimore, Maryland 21201, USA
Clin Gastroenterol Hepatol 6:575-83. 2008.... - Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activityEithan Galun
Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel
J Hepatol 46:37-44. 2007..A Phase 1 clinical trial was designed to test safety, tolerability, and antiviral activity of HCV-AB68 in patients with chronic HCV-infection... - The changing epidemiology and natural history of hepatitis C virus infectionStephanie R Bialek
Division of Viral Hepatitis, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA
Clin Liver Dis 10:697-715. 2006..Emerging risk factors for disease progression include steatosis, insulin resistance (and factors associated with the metabolic syndrome), and host genetics... - Outcomes of donor evaluation in adult-to-adult living donor liver transplantationJames F Trotter
Department of Surgery, University of Colorado, Denver, CO, USA
Hepatology 46:1476-84. 2007..CONCLUSION: Both donor and recipient features appear to affect acceptance for LDLT. These findings may aid the donor evaluation process and allow an objective assessment of the likelihood of donor candidate acceptance... - Burden of liver disease in the United States: summary of a workshopW Ray Kim
Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
Hepatology 36:227-42. 2002 - Sex and hepatitis CNorah A Terrault
Am J Gastroenterol 100:825-6. 2005
Research Grants
- Resistance to Antiviral Therapy in Chronic Hepatitis CNorah Terrault; Fiscal Year: 2005..Moreover, the methodologies developed for patient outreach within the context of this collaborative study will serve as a model for enhancing participation of African Americans in clinical research. ..